gemcitabine has been researched along with saracatinib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, E; Gauthier, I; Gill, S; Goel, R; Hedley, D; Jonker, D; McIntosh, L; Moore, MJ; Renouf, DJ; Seymour, L; Southwood, B; Walde, D; Walsh, W | 1 |
| Hu, XC; Lin, C; Liu, MM; Tao, ZH; Wu, ZH; Zhang, J | 1 |
| Baric, RS; Go, YY; Jung, E; Kim, M; Shin, JS | 1 |
1 review(s) available for gemcitabine and saracatinib
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
1 trial(s) available for gemcitabine and saracatinib
| Article | Year |
|---|---|
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Canada; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Tumor Burden | 2012 |
4 other study(ies) available for gemcitabine and saracatinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzodioxoles; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Focal Adhesion Kinase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase 3; Octamer Transcription Factor-3; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Survivin; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2016 |
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.
Topics: Antiviral Agents; Benzodioxoles; Cell Line; Cross Infection; Deoxycytidine; DNA Replication; Drug Discovery; Enzyme Inhibitors; Gemcitabine; Humans; Middle East Respiratory Syndrome Coronavirus; Quinazolines; Small Molecule Libraries; src-Family Kinases; Virus Replication | 2018 |